Scott G Filler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1090449/publications.pdf

Version: 2024-02-01

240 papers	24,283 citations	8181 76 h-index	7950 149 g-index
263 all docs	263 docs citations	263 times ranked	16189 citing authors

#	Article	IF	Citations
1	Control of Î²-glucan exposure by the endo-1,3-glucanase Eng1 in Candida albicans modulates virulence. PLoS Pathogens, 2022, 18, e1010192.	4.7	19
2	Systematic Genetic Interaction Analysis Identifies a Transcription Factor Circuit Required for Oropharyngeal Candidiasis. MBio, 2022, 13, e0344721.	4.1	11
3	Plasma Membrane Phosphatidylinositol-4-Phosphate Is Not Necessary for Candida albicans Viability yet Is Key for Cell Wall Integrity and Systemic Infection. MBio, 2022, 13, e0387321.	4.1	5
4	Serum bridging molecules drive candidal invasion of human but not mouse endothelial cells. PLoS Pathogens, 2022, 18, e1010681.	4.7	3
5	Use of the Iron-Responsive RBT5 Promoter for Regulated Expression in Candida albicans. MSphere, 2022, 7, .	2.9	2
6	Identification of Candida glabrata Transcriptional Regulators That Govern Stress Resistance and Virulence. Infection and Immunity, 2021, 89, .	2.2	8
7	Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. Science, 2021, 371, .	12.6	84
8	Identification of Host for Using Whole Cell Affinity Purification. Methods in Molecular Biology, 2021, 2260, 27-36.	0.9	0
9	Activation of EphA2-EGFR signaling in oral epithelial cells by Candida albicans virulence factors. PLoS Pathogens, 2021, 17, e1009221.	4.7	45
10	Determining Aspergillus fumigatus transcription factor expression and function during invasion of the mammalian lung. PLoS Pathogens, 2021, 17, e1009235.	4.7	28
11	Response to Comments on â€œAberrant type 1 immunity drives susceptibility to mucosal fungal infectionsâ€• Science, 2021, 373, eabi8835.	12.6	5
12	Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nature Microbiology, 2021, 6, 313-326.	13.3	53
13	The Globular C1q Receptor Is Required for Epidermal Growth Factor Receptor Signaling during Candida albicans Infection. MBio, 2021, 12, e0271621.	4.1	13
14	Fungal dysbiosis and survival after allo-HCT. Nature Microbiology, 2021, 6, 1473-1474.	13.3	0
15	Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	54
16	GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis. MBio, 2020, 11, .	4.1	69
17	Functional Coupling between the Unfolded Protein Response and Endoplasmic Reticulum/Golgi Ca ²⁺ -ATPases Promotes Stress Tolerance, Cell Wall Biosynthesis, and Virulence of Aspergillus fumigatus. MBio, 2020, 11, .	4.1	17
18	Proteomic profiling of the monothiol glutaredoxin Grx3 reveals its global role in the regulation of iron dependent processes. PLoS Genetics, 2020, 16, e1008881.	3.5	9

#	Article	IF	Citations
19	Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality. PLoS Genetics, 2020, 16, e1008582.	3.5	38
20	Cost effective, experimentally robust differential-expression analysis for human/mammalian, pathogen and dual-species transcriptomics. Microbial Genomics, 2020, 6, .	2.0	0
21	Title is missing!. , 2020, 16, e1008582.		0
22	Title is missing!. , 2020, 16, e1008582.		0
23	Title is missing!. , 2020, 16, e1008582.		0
24	Title is missing!. , 2020, 16, e1008582.		0
25	Title is missing!. , 2020, 16, e1008582.		0
26	Title is missing!. , 2020, 16, e1008582.		0
27	Candidalysin Is Required for Neutrophil Recruitment and Virulence During Systemic Candida albicans Infection. Journal of Infectious Diseases, 2019, 220, 1477-1488.	4.0	72
28	EphA2 Is a Neutrophil Receptor for Candida albicans that Stimulates Antifungal Activity during Oropharyngeal Infection. Cell Reports, 2019, 28, 423-433.e5.	6.4	47
29	Genome Sequence for Candida albicans Clinical Oral Isolate 529L. Microbiology Resource Announcements, 2019, 8, .	0.6	13
30	Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Science Advances, 2019, 5, eaaw1327.	10.3	57
31	Selection of Candida albicans trisomy during oropharyngeal infection results in a commensal-like phenotype. PLoS Genetics, 2019, 15, e1008137.	3.5	43
32	CARD9+ microglia promote antifungal immunity via IL-1Î²- and CXCL1-mediated neutrophil recruitment. Nature Immunology, 2019, 20, 559-570.	14.5	162
33	AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus. MBio, 2019, 10, .	4.1	59
34	Genetic variation of DNA methyltransferase-3A contributes to protection against persistent MRSA bacteremia in patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20087-20096.	7.1	20
35	Aspergillus endocarditis diagnosed by fungemia plus serum antigen testing. Medical Mycology Case Reports, 2019, 23, 1-3.	1.3	8
36	A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasisâ€"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2018, 66, 1928-1936.	5.8	134

#	Article	IF	Citations
37	Candida albicans White-Opaque Switching Influences Virulence but Not Mating during Oropharyngeal Candidiasis. Infection and Immunity, 2018, 86, .	2.2	29
38	Invasive pulmonary mucormycosis and aspergillosis in a patient with decompensated hepatic cirrhosis. Medical Mycology Case Reports, 2018, 21, 12-15.	1.3	6
39	Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy. Nature Chemical Biology, 2018, 14, 135-141.	8.0	32
40	EphA2 is an epithelial cell pattern recognition receptor for fungal Î²-glucans. Nature Microbiology, 2018, 3, 53-61.	13.3	136
41	Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11111-E11119.	7.1	63
42	Proteome Analysis Reveals the Conidial Surface Protein CcpA Essential for Virulence of the Pathogenic FungusAspergillus fumigatus. MBio, 2018, 9, .	4.1	53
43	A possible role for fumagillin in cellular damage during host infection by Aspergillus fumigatus. Virulence, 2018, 9, 1548-1561.	4.4	37
44	Targeted enrichment outperforms other enrichment techniques and enables more multi-species RNA-Seq analyses. Scientific Reports, 2018, 8, 13377.	3.3	17
45	The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. PLoS Pathogens, 2018, 14, e1007056.	4.7	43
46	Functional convergence of gliP and aspf1 in Aspergillus fumigatus pathogenicity. Virulence, 2018, 9, 1062-1073.	4.4	14
47	Candida albicans Cannot Acquire Sufficient Ethanolamine from the Host To Support Virulence in the Absence of De Novo Phosphatidylethanolamine Synthesis. Infection and Immunity, 2018, 86, .	2.2	15
48	Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. Frontiers in Immunology, 2018, 9, 1349.	4.8	27
49	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.2	81
50	Rapid Phenotypic and Genotypic Diversification After Exposure to the Oral Host Niche in Candida albicans. Genetics, 2018, 209, 725-741.	2.9	82
51	Inhibition of EGFR Signaling Protects from Mucormycosis. MBio, 2018, 9, .	4.1	45
52	Comparative transcriptomics of Aspergillus fumigatus strains upon exposure to human airway epithelial cells. Microbial Genomics, 2018, 4, .	2.0	18
53	The Case for Adopting the â€œSpecies Complexâ€•Nomenclature for the Etiologic Agents of Cryptococcosis. MSphere, 2017, 2, .	2.9	274
54	Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7124-7129.	7.1	88

#	Article	IF	Citations
55	The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio, 2017, 8, .	4.1	50
56	Aspergillus fumigatus CalA binds to integrin Î±5Î²1 and mediates host cell invasion. Nature Microbiology, 2017, 2, 16211.	13.3	75
57	Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus. Infection and Immunity, 2017, 85, .	2.2	38
58	Yeast casein kinase 2 governs morphology, biofilm formation, cell wall integrity, and host cell damage of Candida albicans. PLoS ONE, 2017, 12, e0187721.	2.5	24
59	Oropharyngeal Candidiasis: Fungal Invasion and Epithelial Cell Responses. PLoS Pathogens, 2017, 13, e1006056.	4.7	87
60	Role of Arf GTPases in fungal morphogenesis and virulence. PLoS Pathogens, 2017, 13, e1006205.	4.7	44
61	An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nature Communications, 2016, 7, 12218.	12.8	103
62	IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis. Cell Host and Microbe, 2016, 20, 606-617.	11.0	148
63	Gene Expression Profiling of Infecting Microbes Using a Digital Bar-coding Platform. Journal of Visualized Experiments, 2016, , e53460.	0.3	1
64	Deacetylation of Fungal Exopolysaccharide Mediates Adhesion and Biofilm Formation. MBio, 2016, 7, e00252-16.	4.1	91
65	Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. Journal of Clinical Investigation, 2016, 126, 2280-2294.	8.2	84
66	Using Bayesian modelling to investigate factors governing antibiotic-induced Candida albicans colonization of the GI tract. Scientific Reports, 2015, 5, 8131.	3.3	34
67	CX ₃ CR1 Is Dispensable for Control of Mucosal Candida albicans Infections in Mice and Humans. Infection and Immunity, 2015, 83, 958-965.	2.2	31
68	A systematic evaluation of high-dimensional, ensemble-based regression for exploring large model spaces in microbiome analyses. BMC Bioinformatics, 2015, 16, 31.	2.6	16
69	Activation and Alliance of Regulatory Pathways in C. albicans during Mammalian Infection. PLoS Biology, 2015, 13, e1002076.	5.6	97
70	Candida albicans cell shaving uncovers new proteins involved in cell wall integrity, yeast to hypha transition, stress response and hostâ€“pathogen interaction. Journal of Proteomics, 2015, 127, 340-351.	2.4	68
71	New signaling pathways govern the host response to C. albicans infection in various niches. Genome Research, 2015, 25, 679-689.	5.5	82
72	Divergent Targets of Aspergillus fumigatus AcuK and AcuM Transcription Factors during Growth In Vitro versus Invasive Disease. Infection and Immunity, 2015, 83, 923-933.	2.2	29

#	Article	IF	Citations
73	Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus. Infection and Immunity, 2015, 83, 4427-4437.	2.2	58
74	Host Cell Invasion by Medically Important Fungi. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019687-a019687.	6.2	56
75	Systemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue. Microbiology (United Kingdom), 2015, 161, 168-181.	1.8	209
76	The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps. PLoS Pathogens, 2015, 11, e1005187.	4.7	167
77	In vitro models of hematogenously disseminated candidiasis. Virulence, 2014, 5, 240-242.	4.4	2
78	Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus. Frontiers in Immunology, 2014, 5, 463.	4.8	21
79	The pH-Responsive PacC Transcription Factor of Aspergillus fumigatus Governs Epithelial Entry and Tissue Invasion during Pulmonary Aspergillosis. PLoS Pathogens, 2014, 10, e1004413.	4.7	151
80	Cryptococcus gattii VGIII Isolates Causing Infections in HIV/AIDS Patients in Southern California: Identification of the Local Environmental Source as Arboreal. PLoS Pathogens, 2014, 10, e1004285.	4.7	85
81	Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5555-63.	7.1	61
82	Different tumor necrosis factor Î± antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice. Virulence, 2014, 5, 625-629.	4.4	9
83	Overlapping and Distinct Roles of Aspergillus fumigatus UDP-glucose 4-Epimerases in Galactose Metabolism and the Synthesis of Galactose-containing Cell Wall Polysaccharides. Journal of Biological Chemistry, 2014, 289, 1243-1256.	3.4	102
84	Role of Retrograde Trafficking in Stress Response, Host Cell Interactions, and Virulence of Candida albicans. Eukaryotic Cell, 2014, 13, 279-287.	3.4	32
85	CotH3 mediates fungal invasion of host cells during mucormycosis. Journal of Clinical Investigation, 2014, 124, 237-250.	8.2	185
86	Can host receptors for fungi be targeted for treatment of fungal infections?. Trends in Microbiology, 2013, 21, 389-396.	7.7	12
87	Genome Mining of a Prenylated and Immunosuppressive Polyketide from Pathogenic Fungi. Organic Letters, 2013, 15, 780-783.	4.6	89
88	NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine, 2013, 31, 5549-5556.	3.8	79
89	Synergistic Regulation of Hyphal Elongation by Hypoxia, CO2, and Nutrient Conditions Controls the Virulence of Candida albicans. Cell Host and Microbe, 2013, 14, 499-509.	11.0	65
90	Role of Endothelial Cell Septin 7 in the Endocytosis of Candida albicans. MBio, 2013, 4, e00542-13.	4.1	38

#	Article	IF	Citations
91	Candida albicans CUG Mistranslation Is a Mechanism To Create Cell Surface Variation. MBio, 2013, 4, .	4.1	77
92	Regulatory Role of Glycerol in Candida albicans Biofilm Formation. MBio, 2013, 4, e00637-12.	4.1	77
93	Pharmacokinetics of Posaconazole Within Epithelial Cells and Fungi: Insights Into Potential Mechanisms of Action During Treatment and Prophylaxis. Journal of Infectious Diseases, 2013, 208, 1717-1728.	4.0	45
94	Aspergillus Galactosaminogalactan Mediates Adherence to Host Constituents and Conceals Hyphal Î²-Glucan from the Immune System. PLoS Pathogens, 2013, 9, e1003575.	4.7	256
95	Bcr1 Functions Downstream of Ssd1 To Mediate Antimicrobial Peptide Resistance in Candida albicans. Eukaryotic Cell, 2013, 12, 411-419.	3.4	19
96	Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 3340-3347.	3.2	54
97	SR-Like RNA-Binding Protein Slr1 Affects Candida albicans Filamentation and Virulence. Infection and Immunity, 2013, 81, 1267-1276.	2.2	37
98	Glycerophosphocholine Utilization by Candida albicans. Journal of Biological Chemistry, 2013, 288, 33939-33952.	3.4	35
99	Investigation of the Function of Candida albicans Als3 by Heterologous Expression in Candida glabrata. Infection and Immunity, 2013, 81, 2528-2535.	2.2	35
100	Divergent Targets of Candida albicans Biofilm Regulator Bcr1 In Vitro and In Vivo. Eukaryotic Cell, 2012, 11, 896-904.	3.4	103
101	NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine, 2012, 30, 7594-7600.	3.8	177
102	EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14194-14199.	7.1	152
103	Insights from human studies into the host defense against candidiasis. Cytokine, 2012, 58, 129-132.	3.2	17
104	Mouse model of oropharyngeal candidiasis. Nature Protocols, 2012, 7, 637-642.	12.0	181
105	Divergent Responses of Different Endothelial Cell Types to Infection with Candida albicans and Staphylococcus aureus. PLoS ONE, 2012, 7, e39633.	2.5	27
106	Editorial overview. Current Opinion in Microbiology, 2011, 14, 373-374.	5.1	0
107	In vitro endothelial cell damage is positively correlated with enhanced virulence and poor vancomycin responsiveness in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Cellular Microbiology, 2011, 13, 1530-1541.	2.1	46
108	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis. Eukaryotic Cell, 2011, 10, 803-819.	3.4	97

#	Article	IF	Citations
109	Mechanisms of Candida albicans Trafficking to the Brain. PLoS Pathogens, 2011, 7, e1002305.	4.7	74
110	Candida albicans Als3, a Multifunctional Adhesin and Invasin. Eukaryotic Cell, 2011, 10, 168-173.	3.4	263
111	Mucormycosis and Entomophthoramycosis (Zygomycosis). , 2011, , 265-280.		16
112	Aspergillus fumigatus AcuM regulates both iron acquisition and gluconeogenesis. Molecular Microbiology, 2010, 78, 1038-1054.	2.5	53
113	Aspergillus fumigatusMedA governs adherence, host cell interactions and virulence. Cellular Microbiology, 2010, 12, 473-488.	2.1	124
114	Interactions ofCandida albicanswith epithelial cells. Cellular Microbiology, 2010, 12, 273-282.	2.1	198
115	Role of Aspergillus fumigatus DvrA in Host Cell Interactions and Virulence. Eukaryotic Cell, 2010, 9, 1432-1440.	3.4	31
116	Role of Trehalose Biosynthesis in Aspergillus fumigatus Development, Stress Response, and Virulence. Infection and Immunity, 2010, 78, 3007-3018.	2.2	136
117	Host Cell Invasion and Virulence Mediated by Candida albicans Ssa1. PLoS Pathogens, 2010, 6, e1001181.	4.7	170
118	Elucidating the Candida albicans calcineurin signaling cascade controlling stress response and virulence. Fungal Genetics and Biology, 2010, 47, 107-116.	2.1	75
119	The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. Journal of Clinical Investigation, 2010, 120, 1914-1924.	8.2	240
120	A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIVâ€Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2009, 48, 1775-1783.	5.8	141
121	Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. Journal of Experimental Medicine, 2009, 206, 299-311.	8.5	878
122	An RNA Transport System in Candida albicans Regulates Hyphal Morphology and Invasive Growth. PLoS Genetics, 2009, 5, e1000664.	3.5	69
123	Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. Clinical Infectious Diseases, 2009, 49, 931-934.	5.8	103
124	Transcriptional Responses of Candida albicans to Epithelial and Endothelial Cells. Eukaryotic Cell, 2009, 8, 1498-1510.	3.4	54
125	The Aspergillus fumigatus transcription factor Ace2 governs pigment production, conidiation and virulence. Molecular Microbiology, 2009, 72, 155-169.	2.5	45
126	Polarized response of endothelial cells to invasion byAspergillus fumigatus. Cellular Microbiology, 2009, 11, 170-182.	2.1	29

#	Article	IF	Citations
127	Candida albicansinternalization by host cells is mediated by a clathrin-dependent mechanism. Cellular Microbiology, 2009, 11, 1179-1189.	2.1	128
128	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	5.8	2,644
129	Endothelial Cell Stimulation by Candida albicans. Methods in Molecular Biology, 2009, 470, 313-326.	0.9	5
130	Candida albicanstranscription factor Rim101 mediates pathogenic interactions through cell wall functions. Cellular Microbiology, 2008, 10, 2180-2196.	2.1	144
131	Complementary Adhesin Function in C. albicans Biofilm Formation. Current Biology, 2008, 18, 1017-1024.	3.9	293
132	Gliotoxin Production inAspergillus fumigatusContributes to Hostâ€Specific Differences in Virulence. Journal of Infectious Diseases, 2008, 197, 479-486.	4.0	196
133	Combination Polyeneâ€Caspofungin Treatment of Rhinoâ€Orbitalâ€Cerebral Mucormycosis. Clinical Infectious Diseases, 2008, 47, 364-371.	5.8	424
134	Transcriptome Profile of the Vascular Endothelial Cell Response toCandida albicans. Journal of Infectious Diseases, 2008, 198, 193-202.	4.0	39
135	The Yak1 Kinase Is Involved in the Initiation and Maintenance of Hyphal Growth inCandida albicans. Molecular Biology of the Cell, 2008, 19, 2251-2266.	2.1	59
136	The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the BacteriumStaphylococcus aureus. Infection and Immunity, 2008, 76, 4574-4580.	2.2	133
137	SSD1 Is Integral to Host Defense Peptide Resistance in Candida albicans. Eukaryotic Cell, 2008, 7, 1318-1327.	3.4	38
138	In Vivo Analysis of Aspergillus fumigatus Developmental Gene Expression Determined by Real-Time Reverse Transcription-PCR. Infection and Immunity, 2008, 76, 3632-3639.	2.2	48
139	The Hyphal-Associated Adhesin and Invasin Als3 of Candida albicans Mediates Iron Acquisition from Host Ferritin. PLoS Pathogens, 2008, 4, e1000217.	4.7	259
140	Aspergillus fumigatus Stimulates Leukocyte Adhesion Molecules and Cytokine Production by Endothelial Cells In Vitro and during Invasive Pulmonary Disease. Infection and Immunity, 2008, 76, 3429-3438.	2.2	56
141	Requirement for Candida albicans Sun41 in Biofilm Formation and Virulence. Eukaryotic Cell, 2007, 6, 2046-2055.	3.4	118
142	Als3 Is a Candida albicans Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells. PLoS Biology, 2007, 5, e64.	5.6	492
143	Pharmacokinetics of Murine p75-Fc Fusion Protein and MP6-XT22 Anti-Murine TNF-Î± mAb in Mice. Journal of Investigative Dermatology Symposium Proceedings, 2007, 12, 52-56.	0.8	13
144	Candida albicans protein kinase CK2 governs virulence during oropharyngeal candidiasis. Cellular Microbiology, 2007, 9, 233-245.	2.1	50

#	Article	IF	Citations
145	In vivo and ex vivo comparative transcriptional profiling of invasive and non-invasive Candida albicans isolates identifies genes associated with tissue invasion. Molecular Microbiology, 2007, 63, 1606-1628.	2.5	134
146	Current Treatment Strategies for Disseminated Candidiasis. Clinical Infectious Diseases, 2006, 42, 244-251.	5.8	227
147	Candidaâ€“host cell receptorâ€“ligand interactions. Current Opinion in Microbiology, 2006, 9, 333-339.	5.1	82
148	Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. Clinical Microbiology and Infection, 2006, 12, 376-380.	6.0	66
149	Efficacy of the Antiâ€CandidarAls3pâ€N or rAls1pâ€N Vaccines against Disseminated and Mucosal Candidiasis. Journal of Infectious Diseases, 2006, 194, 256-260.	4.0	162
150	Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2006, 50, 2751-2755.	3.2	129
151	Standardization of an Experimental Murine Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 3501-3503.	3.2	51
152	Efficacy of Ambruticin Analogs in a Murine Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 3464-3466.	3.2	11
153	Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo. PLoS Pathogens, 2006, 2, e63.	4.7	443
154	Candida albicans Ecm33p Is Important for Normal Cell Wall Architecture and Interactions with Host Cells. Eukaryotic Cell, 2006, 5, 140-147.	3.4	77
155	Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureus. New England Journal of Medicine, 2006, 355, 653-665.	27.0	1,347
156	Fungal Invasion of Normally Non-Phagocytic Host Cells. PLoS Pathogens, 2006, 2, e129.	4.7	237
157	Interactions of Fungi with Endothelial Cells. , 2005, , 403-419.		0
158	Vaccination with Recombinant N-Terminal Domain of Als1p Improves Survival during Murine Disseminated Candidiasis by Enhancing Cell-Mediated, Not Humoral, Immunity. Infection and Immunity, 2005, 73, 999-1005.	2.2	74
159	Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2005, 49, 952-958.	3.2	212
160	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases, 2005, 41, 1473-1480.	5.8	72
161	Mice with Disseminated Candidiasis Die of Progressive Sepsis. Journal of Infectious Diseases, 2005, 192, 336-343.	4.0	196
162	The Anti- Candida albicans Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised Mice. Infection and Immunity, 2005, 73, 6191-6193.	2.2	69

#	Article	IF	Citations
163	TheAspergillus fumigatusStuA Protein Governs the Up-Regulation of a Discrete Transcriptional Program during the Acquisition of Developmental Competence. Molecular Biology of the Cell, 2005, 16, 5866-5879.	2.1	114
164	N-cadherin Mediates Endocytosis of Candida albicans by Endothelial Cells. Journal of Biological Chemistry, 2005, 280, 10455-10461.	3.4	100
165	Tumor Necrosis Factor Inhibition and Invasive Fungal Infections. Clinical Infectious Diseases, 2005, 41, S208-S212.	5.8	99
166	Functional and Structural Diversity in the Als Protein Family of Candida albicans. Journal of Biological Chemistry, 2004, 279, 30480-30489.	3.4	254
167	Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2004, 48, 1908-1911.	3.2	135
168	Role of the fungal Ras-protein kinase A pathway in governing epithelial cell interactions during oropharyngeal candidiasis. Cellular Microbiology, 2004, 7, 499-510.	2.1	182
169	Functional analysis of theCandida albicans ALS1 gene product. Yeast, 2004, 21, 473-482.	1.7	77
170	Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality, 2004, 16, 79-85.	2.6	62
171	Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases, 2004, 38, 161-189.	5.8	1,371
172	Relationship between Candida albicans Virulence during Experimental Hematogenously Disseminated Infection and Endothelial Cell Damage In Vitro. Infection and Immunity, 2004, 72, 598-601.	2.2	98
173	Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood, 2004, 103, 2143-2149.	1.4	108
174	Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei. Antimicrobial Agents and Chemotherapy, 2003, 47, 1213-1219.	3.2	93
175	Parenchymal Organ, and Not Splenic, Immunity Correlates with Host Survival during Disseminated Candidiasis. Infection and Immunity, 2003, 71, 5756-5764.	2.2	62
176	Calcineurin Is Essential for Candida albicans Survival in Serum and Virulence. Eukaryotic Cell, 2003, 2, 422-430.	3.4	177
177	A Forkhead Transcription Factor Is Important for True Hyphal as well as Yeast Morphogenesis in Candida albicans. Eukaryotic Cell, 2002, 1, 787-798.	3.4	114
178	Contribution of Candida albicans ALS1 to the Pathogenesis of Experimental Oropharyngeal Candidiasis. Infection and Immunity, 2002, 70, 5256-5258.	2.2	71
179	Candida albicansStimulates Local Expression of Leukocyte Adhesion Molecules and Cytokines In Vivo. Journal of Infectious Diseases, 2002, 186, 389-396.	4.0	30
180	Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Molecular Microbiology, 2002, 44, 61-72.	2.5	203

#	Article	IF	Citations
181	Endocytosis ofCandida albicansby vascular endothelial cells is associated with tyrosine phosphorylation of specific host cell proteins. Cellular Microbiology, 2002, 4, 805-812.	2.1	33
182	Candida albicans Mds3p, a Conserved Regulator of pH Responses and Virulence Identified Through Insertional Mutagenesis. Genetics, 2002, 162, 1573-1581.	2.9	189
183	Eukaryotic Translation Initiation Factor-6 Enhances Histamine and IL-2 Production in Mast Cells. Journal of Immunology, 2001, 166, 3606-3611.	0.8	13
184	New Model of Oropharyngeal Candidiasis in Mice. Antimicrobial Agents and Chemotherapy, 2001, 45, 3195-3197.	3.2	99
185	Role of Hyphal Formation in Interactions of Candida albicans with Endothelial Cells. Infection and Immunity, 2000, 68, 3485-3490.	2.2	178
186	Reduced Virulence of HWP1 -Deficient Mutants of Candida albicans and Their Interactions with Host Cells. Infection and Immunity, 2000, 68, 1997-2002.	2.2	114
187	Mechanisms of the Proinflammatory Response of Endothelial Cells toCandida albicansInfection. Infection and Immunity, 2000, 68, 1134-1141.	2.2	79
188	Practice Guidelines for the Treatment of Candidiasis. Clinical Infectious Diseases, 2000, 30, 662-678.	5.8	833
189	Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects. Circulation, 1999, 99, 2791-2797.	1.6	157
190	Unanticipated Heterogeneity in Growth Rate and Virulence among Candida albicans AAF1 Null Mutants. Infection and Immunity, 1999, 67, 3193-3198.	2.2	35
191	Mechanism of Fluconazole Resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 1998, 42, 2645-2649.	3.2	196
192	Endothelial Cell Injury Caused by Candida albicans Is Dependent on Iron. Infection and Immunity, 1998, 66, 191-196.	2.2	37
193	Expression of the Candida albicans Gene ALS1 in Saccharomyces cerevisiae Induces Adherence to Endothelial and Epithelial Cells. Infection and Immunity, 1998, 66, 1783-1786.	2.2	154
194	Cloning and Characterization ofCAD1/AAF1, a Gene fromCandida albicansThat Induces Adherence to Endothelial Cells after Expression inSaccharomyces cerevisiae. Infection and Immunity, 1998, 66, 2078-2084.	2.2	33
195	Secreted Aspartyl Proteinases and Interactions of Candida albicans with Human Endothelial Cells. Infection and Immunity, 1998, 66, 3003-3005.	2.2	56
196	International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clinical Infectious Diseases, 1997, 25, 43-59.	5.8	438
197	Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrobial Agents and Chemotherapy, 1997, 41, 535-539.	3.2	64
198	Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infection and Immunity, 1995, 63, 4368-4374.	2.2	72

#	Article	IF	Citations
199	Evidence implicating phospholipase as a virulence factor of Candida albicans. Infection and Immunity, 1995, 63, 1993-1998.	2.2	313
200	Severe Candidal Infections in Neutropenic Patients. Clinical Infectious Diseases, 1993, 17, S457-S467.	5.8	61
201	Current Strategies for Treating Invasive Candidiasis: Emphasis on Infections in Nonneutropenic Patients. Clinical Infectious Diseases, 1992, 14, S106-S113.	5.8	76
202	Candida albicans adherence to endothelial cells. Microvascular Research, 1992, 43, 218-226.	2.5	21
203	Fungal Molecular Pathogenesis: What Can It Do and Why Do We Need It?. , 0, , 1-11.		9
204	Signal Transduction in the Interactions of Fungal Pathogens and Mammalian Hosts. , 0, , 143-162.		2
205	Function and Regulation of Adhesin Gene Families inSaccharomyces cerevisiae, Candida albicans, andCandida glabrata. , 0, , 163-175.		4
206	Fungal Biofilms: Agents of Disease and Drug Resistance. , 0, , 177-185.		3
207	Molecular Basis of Fungal Adherence to Endothelial and Epithelial Cells. , 0, , 187-196.		3
208	Molecular Principles of Antifungal Drug Resistance. , 0, , 197-212.		7
209	Saccharomyces cerevisiae: an Emerging and Model Pathogenic Fungus. , 0, , 245-259.		12
210	Sex, MAT, and the Evolution of Fungal Virulence. , 0, , 13-33.		5
211	Amphibian Chytridiomycosis as an Emerging Infectious Disease of Wildlife: What Can We Learn from the Earliest Diverging Fungi?. , 0, , 271-278.		1
212	Cryptococcus neoformans : a Sugar-Coated Killer. , 0, , 279-303.		6
213	Toward a Molecular Understanding ofCandida albicansVirulence. , 0, , 305-P1.		10
214	Molecular Determinants of Histoplasma capsulatum Pathogenesis. , 0, , 321-331.		2
215	Molecular Determinants of Virulence in Aspergillus fumigatus. , 0, , 333-345.		7
216	Virulence Mechanisms of Coccidioides. , 0, , 363-391.		12

#	Article	IF	Citations
217	Virulence Factors in Black Molds with Emphasis on Melanin, Chitin, and Wangiella as a Molecularly Tractable Model. , 0, , 407-428.		10
218	Zygomycetes as Agents of Infectious Disease in Humans. , 0, , 429-440.		8
219	Signaling Pathways in the Dimorphic Human Fungal PathogenPenicillium marneffei. , 0, , 441-454.		4
220	Innate and Acquired Cellular Immunity to Fungi. , 0, , 471-486.		4
221	Acquired Antibody-Mediated Immunity to Fungi. , 0, , 487-503.		1
222	Site-Specific Mucosal Immunity to Fungi: Lessons Learned from Candida albicans Applied to Other Fungi. , 0, , 505-526.		1
223	Intracellular Pathogenesis of Histoplasma capsulatum. , 0, , 527-536.		2
224	Fungal Interactions with Leukocytes. , 0, , 555-563.		1
225	Fungal Vaccine Development. , 0, , 565-581.		1
226	Candida albicans Hypha Formation and Virulence. , 0, , 45-P2.		10
227	Future of Functional Genomics of Histoplasma capsulatum. , 0, , 611-625.		1
228	Functional Genomic Approaches to Fungal Pathogenesis, Drug Target Validation, and Antifungal Drug Discovery. , 0, , 627-642.		1
229	The Mating-Type Locus and Mating of Candida albicans and Candida glabrata. , 0, , 89-112.		1
230	Evolution of Human-Pathogenic Fungi: Phylogenies and Species. , 0, , 113-P1.		5
231	Heterologous Hosts and the Evolution and Study of Fungal Pathogenesis. , 0, , 213-225.		0
232	Interactions of Aspergillus with the Mucosa. , 0, , 239-245.		0
233	Postgenomic Strategies for Genetic Analysis: Insight from Saccharomyces cerevisiae and Candida albicans. , 0, , 35-P1.		0
234	Studying Fungal Virulence by Using Genomics. , 0, , 589-P1.		1

#	Article	IF	Citations
235	Candida: What Should Clinicians and Scientists Be Talking About?. , 0, , 1-8.		6
236	Amoeba and Slime Mold: Hosts of Virulence Evolution. , 0, , 227-234.		0
237	Aspergillus nidulans: a Model for Elucidation ofAspergillus fumigatusSecondary Metabolism. , 0, , 235-243.		0
238	The Conversion from Classical Studies in Fungal Pathogenesis to the Molecular Era. , 0, , 49-P1.		0
239	Establishment of Cell Identity in Pathogenic Fungi. , 0, , 133-141.		0
240	EphA2 is a Neutrophil Receptor for Candida Albicans that Stimulates Antifungal Activity During Oropharyngeal Infection. SSRN Electronic Journal, 0, , .	0.4	0